ROCKVILLE, Md., Oct. 29, 2024 /PRNewswire/ — Eilean Therapeutics LLC, a biopharmaceutical company targeting escape mutations in hematologic and solid malignancies, today announced that an abstract related to the company’s first-in-class oral MALT1 degrader has been accepted for a poster…